JPWO2020146440A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020146440A5 JPWO2020146440A5 JP2021539935A JP2021539935A JPWO2020146440A5 JP WO2020146440 A5 JPWO2020146440 A5 JP WO2020146440A5 JP 2021539935 A JP2021539935 A JP 2021539935A JP 2021539935 A JP2021539935 A JP 2021539935A JP WO2020146440 A5 JPWO2020146440 A5 JP WO2020146440A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- active agent
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013543 active substance Substances 0.000 claims description 22
- 208000034578 Multiple myelomas Diseases 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
- 229940125782 compound 2 Drugs 0.000 claims description 5
- 229940125904 compound 1 Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 61
- 239000003112 inhibitor Substances 0.000 claims 47
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 8
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 7
- 102100039489 Histone-lysine N-methyltransferase, H3 lysine-79 specific Human genes 0.000 claims 7
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 7
- 101000963360 Homo sapiens Histone-lysine N-methyltransferase, H3 lysine-79 specific Proteins 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 229940124291 BTK inhibitor Drugs 0.000 claims 5
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 claims 5
- 229940124647 MEK inhibitor Drugs 0.000 claims 5
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 claims 5
- 229940124302 mTOR inhibitor Drugs 0.000 claims 5
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 5
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 5
- 229960004066 trametinib Drugs 0.000 claims 5
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical group CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 5
- 102100032306 Aurora kinase B Human genes 0.000 claims 4
- 108091005625 BRD4 Proteins 0.000 claims 4
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 4
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 claims 4
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 claims 4
- 102100029095 Exportin-1 Human genes 0.000 claims 4
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 claims 4
- 101000601441 Homo sapiens Serine/threonine-protein kinase Nek2 Proteins 0.000 claims 4
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 claims 4
- 102100037703 Serine/threonine-protein kinase Nek2 Human genes 0.000 claims 4
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 4
- 108010002687 Survivin Proteins 0.000 claims 4
- 101150094313 XPO1 gene Proteins 0.000 claims 4
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 4
- 108700002148 exportin 1 Proteins 0.000 claims 4
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical group C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims 4
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 4
- 229950004774 tazemetostat Drugs 0.000 claims 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- VRQXRVAKPDCRCI-ZNMIVQPWSA-N n-[4-[(1r,3s,5s)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide Chemical group C1[C@H](C)C[C@H](N)C[C@@H]1C1=CC=NC=C1NC(=O)C1=CC=C(F)C(C=2C(=CC=CC=2F)F)=N1 VRQXRVAKPDCRCI-ZNMIVQPWSA-N 0.000 claims 3
- 229960001308 trametinib dimethyl sulfoxide Drugs 0.000 claims 3
- OQUFJVRYDFIQBW-UHFFFAOYSA-N trametinib dimethyl sulfoxide Chemical compound CS(C)=O.CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 OQUFJVRYDFIQBW-UHFFFAOYSA-N 0.000 claims 3
- IQCKJUKAQJINMK-HUBRGWSESA-N 1-[3-[[(2r,3s,4r,5r)-5-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea Chemical group C([C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C2=NC=NC(N)=C2C(Br)=C1)O)N(C(C)C)CCCNC(=O)NC1=CC=C(C(C)(C)C)C=C1 IQCKJUKAQJINMK-HUBRGWSESA-N 0.000 claims 2
- LXFOLMYKSYSZQS-LURJZOHASA-N CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1 Chemical compound CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1 LXFOLMYKSYSZQS-LURJZOHASA-N 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 2
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical group N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 claims 2
- 229950003487 fedratinib Drugs 0.000 claims 2
- 229960001507 ibrutinib Drugs 0.000 claims 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical group C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 2
- HPODOLXTMDHLLC-QGZVFWFLSA-N n-[(4-methoxy-6-methyl-2-oxo-1h-pyridin-3-yl)methyl]-2-methyl-1-[(1r)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]ethyl]indole-3-carboxamide Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C3=CC=CC=C3N([C@H](C)C3CCN(CC(F)(F)F)CC3)C=2C)=C1OC HPODOLXTMDHLLC-QGZVFWFLSA-N 0.000 claims 2
- DPJNKUOXBZSZAI-UHFFFAOYSA-N n-[(6-methyl-2-oxo-4-propyl-1h-pyridin-3-yl)methyl]-1-propan-2-yl-6-[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]indazole-4-carboxamide Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C=3C=NN(C=3C=C(C=2)C=2C=NC(=CC=2)N2CCN(CC2)C(C)C)C(C)C)=C1CCC DPJNKUOXBZSZAI-UHFFFAOYSA-N 0.000 claims 2
- 229950006101 pinometostat Drugs 0.000 claims 2
- LMXOHSDXUQEUSF-YECHIGJVSA-N sinefungin Chemical compound O[C@@H]1[C@H](O)[C@@H](C[C@H](CC[C@H](N)C(O)=O)N)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LMXOHSDXUQEUSF-YECHIGJVSA-N 0.000 claims 2
- MCUJKPPARUPFJM-UWCCDQBKSA-N (5z)-5-[[2-[(3r)-3-aminopiperidin-1-yl]-3-phenylphenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1[C@H](N)CCCN1C(C(=CC=C1)C=2C=CC=CC=2)=C1\C=C/1C(=O)NC(=O)S\1 MCUJKPPARUPFJM-UWCCDQBKSA-N 0.000 claims 1
- FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 claims 1
- ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]-4-indazolecarboxamide Chemical compound O=C1NC(C)=CC(C)=C1CNC(=O)C1=CC(C=2C=CC(CN3CCOCC3)=CC=2)=CC2=C1C=NN2C1CCCC1 ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 0.000 claims 1
- OMKHWTRUYNAGFG-IEBDPFPHSA-N 3-deazaneplanocin a Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1C=C(CO)[C@@H](O)[C@H]1O OMKHWTRUYNAGFG-IEBDPFPHSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- PFHDWRIVDDIFRP-UHFFFAOYSA-N 6-cyano-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-1-pentan-3-ylindole-4-carboxamide Chemical compound C1=C(C#N)C=C2N(C(CC)CC)C=CC2=C1C(=O)NCC1=C(C)C=C(C)NC1=O PFHDWRIVDDIFRP-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- QYZOGCMHVIGURT-UHFFFAOYSA-N AZD-1152 Chemical compound N=1C=NC2=CC(OCCCN(CCO)CC)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 QYZOGCMHVIGURT-UHFFFAOYSA-N 0.000 claims 1
- XRNVABDYQLHODA-JCNLHEQBSA-N CC(C)(O)[C@H]1CC[C@@H](CC1)NC1=NN2C(C=C1)=NC=C2C1=CC=CC(=C1)C(F)(F)F Chemical compound CC(C)(O)[C@H]1CC[C@@H](CC1)NC1=NN2C(C=C1)=NC=C2C1=CC=CC(=C1)C(F)(F)F XRNVABDYQLHODA-JCNLHEQBSA-N 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- SQSZANZGUXWJEA-UHFFFAOYSA-N Gandotinib Chemical compound N1C(C)=CC(NC2=NN3C(CC=4C(=CC(Cl)=CC=4)F)=C(C)N=C3C(CN3CCOCC3)=C2)=N1 SQSZANZGUXWJEA-UHFFFAOYSA-N 0.000 claims 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 claims 1
- MHXGEROHKGDZGO-UHFFFAOYSA-N N-[(1-methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-6-imidazo[1,2-b]pyridazinamine Chemical compound C1CN(C)CCC1CNC1=NN2C(C=3C=C(OC(F)(F)F)C=CC=3)=CN=C2C=C1 MHXGEROHKGDZGO-UHFFFAOYSA-N 0.000 claims 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 claims 1
- 229950009821 acalabrutinib Drugs 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- 229950000971 baricitinib Drugs 0.000 claims 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 claims 1
- 229950003054 binimetinib Drugs 0.000 claims 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002271 cobimetinib Drugs 0.000 claims 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229950008908 gandotinib Drugs 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229950001845 lestaurtinib Drugs 0.000 claims 1
- -1 or a stereoisomer Substances 0.000 claims 1
- 229950011410 pacritinib Drugs 0.000 claims 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 claims 1
- 229960000688 pomalidomide Drugs 0.000 claims 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 229960000215 ruxolitinib Drugs 0.000 claims 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims 1
- 229950010746 selumetinib Drugs 0.000 claims 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims 1
- 229950008974 sinefungin Drugs 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024059887A JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962790326P | 2019-01-09 | 2019-01-09 | |
| US62/790,326 | 2019-01-09 | ||
| PCT/US2020/012647 WO2020146440A1 (en) | 2019-01-09 | 2020-01-08 | Antiproliferative compounds and second active agents for use in treating multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059887A Division JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022516974A JP2022516974A (ja) | 2022-03-03 |
| JPWO2020146440A5 true JPWO2020146440A5 (https=) | 2023-01-24 |
| JP2022516974A5 JP2022516974A5 (https=) | 2023-01-24 |
| JP7467479B2 JP7467479B2 (ja) | 2024-04-15 |
Family
ID=69500830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539935A Active JP7467479B2 (ja) | 2019-01-09 | 2020-01-08 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
| JP2024059887A Pending JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059887A Pending JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11660297B2 (https=) |
| EP (2) | EP4461370A3 (https=) |
| JP (2) | JP7467479B2 (https=) |
| KR (1) | KR20210126011A (https=) |
| CN (3) | CN114404596A (https=) |
| AU (1) | AU2020205643C1 (https=) |
| CA (1) | CA3125753A1 (https=) |
| DK (1) | DK3908281T3 (https=) |
| EA (1) | EA202191903A1 (https=) |
| ES (1) | ES2995189T3 (https=) |
| FI (1) | FI3908281T3 (https=) |
| HR (1) | HRP20241309T1 (https=) |
| HU (1) | HUE068895T2 (https=) |
| IL (1) | IL284671B2 (https=) |
| LT (1) | LT3908281T (https=) |
| MX (2) | MX2021008294A (https=) |
| PL (1) | PL3908281T3 (https=) |
| PT (1) | PT3908281T (https=) |
| RS (1) | RS66066B1 (https=) |
| SG (1) | SG11202107413YA (https=) |
| SI (1) | SI3908281T1 (https=) |
| SM (1) | SMT202400388T1 (https=) |
| WO (1) | WO2020146440A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117838695A (zh) * | 2018-04-13 | 2024-04-09 | 住友制药肿瘤公司 | 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂 |
| WO2020146440A1 (en) * | 2019-01-09 | 2020-07-16 | Celgene Corporation | Antiproliferative compounds and second active agents for use in treating multiple myeloma |
| AU2020206692B2 (en) * | 2019-01-09 | 2025-03-27 | Celgene Corporation | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| MX2023009858A (es) * | 2021-02-25 | 2023-09-12 | Impact Biomedicines Inc | Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis. |
| EP4347037A1 (en) | 2021-05-27 | 2024-04-10 | Celgene Corporation | Methods of treating multiple myeloma using combination therapy |
| EP4370127A2 (en) * | 2021-07-12 | 2024-05-22 | Quteba Ebrahem | A method of treating cancer or a blood disorder |
| CN116496246A (zh) * | 2022-01-18 | 2023-07-28 | 中国药科大学 | 异吲哚啉类化合物、制备方法、药物组合物和应用 |
| CN117045800A (zh) * | 2022-05-06 | 2023-11-14 | 上海科技大学 | mTOR抑制剂增强靶向蛋白降解药物功效的应用 |
| CN119015299A (zh) * | 2024-08-21 | 2024-11-26 | 中国医学科学院肿瘤医院 | 西奈芬净在治疗癌症中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| EP2536706B1 (en) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| CA2956550A1 (en) | 2014-08-08 | 2016-02-11 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| WO2016025635A2 (en) * | 2014-08-13 | 2016-02-18 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP4201399A3 (en) | 2017-06-30 | 2023-08-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
| TWI791552B (zh) * | 2017-07-10 | 2023-02-11 | 美商西建公司 | 抗增生化合物及其使用方法 |
| EA202092830A1 (ru) * | 2018-05-23 | 2021-04-08 | Селджин Корпорейшн | Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного применения |
| WO2020146440A1 (en) * | 2019-01-09 | 2020-07-16 | Celgene Corporation | Antiproliferative compounds and second active agents for use in treating multiple myeloma |
-
2020
- 2020-01-08 WO PCT/US2020/012647 patent/WO2020146440A1/en not_active Ceased
- 2020-01-08 ES ES20704117T patent/ES2995189T3/es active Active
- 2020-01-08 CN CN202210009586.2A patent/CN114404596A/zh active Pending
- 2020-01-08 US US16/737,710 patent/US11660297B2/en active Active
- 2020-01-08 CA CA3125753A patent/CA3125753A1/en active Pending
- 2020-01-08 EP EP24191518.0A patent/EP4461370A3/en active Pending
- 2020-01-08 JP JP2021539935A patent/JP7467479B2/ja active Active
- 2020-01-08 AU AU2020205643A patent/AU2020205643C1/en active Active
- 2020-01-08 DK DK20704117.9T patent/DK3908281T3/da active
- 2020-01-08 PT PT207041179T patent/PT3908281T/pt unknown
- 2020-01-08 IL IL284671A patent/IL284671B2/en unknown
- 2020-01-08 EP EP20704117.9A patent/EP3908281B9/en active Active
- 2020-01-08 RS RS20241127A patent/RS66066B1/sr unknown
- 2020-01-08 LT LTEPPCT/US2020/012647T patent/LT3908281T/lt unknown
- 2020-01-08 HR HRP20241309TT patent/HRP20241309T1/hr unknown
- 2020-01-08 SM SM20240388T patent/SMT202400388T1/it unknown
- 2020-01-08 PL PL20704117.9T patent/PL3908281T3/pl unknown
- 2020-01-08 MX MX2021008294A patent/MX2021008294A/es unknown
- 2020-01-08 EA EA202191903A patent/EA202191903A1/ru unknown
- 2020-01-08 KR KR1020217025057A patent/KR20210126011A/ko not_active Ceased
- 2020-01-08 SI SI202130207T patent/SI3908281T1/sl unknown
- 2020-01-08 CN CN202080018980.1A patent/CN113543786A/zh active Pending
- 2020-01-08 SG SG11202107413YA patent/SG11202107413YA/en unknown
- 2020-01-08 CN CN202410171019.6A patent/CN118178417A/zh active Pending
- 2020-01-08 HU HUE20704117A patent/HUE068895T2/hu unknown
- 2020-01-08 FI FIEP20704117.9T patent/FI3908281T3/fi active
-
2021
- 2021-07-08 MX MX2024008439A patent/MX2024008439A/es unknown
-
2023
- 2023-04-25 US US18/139,151 patent/US12186311B2/en active Active
-
2024
- 2024-04-03 JP JP2024059887A patent/JP2024081769A/ja active Pending
- 2024-11-21 US US18/955,085 patent/US20250082629A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230190760A1 (en) | Advantageous therapies for disorders mediated by ikaros or aiolos | |
| ES2521672T3 (es) | Formulaciones farmacéuticas para el tratamiento del cáncer | |
| JP2023515817A (ja) | ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ | |
| KR20180113976A (ko) | 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법 | |
| HRP20241309T1 (hr) | Antiproliferativni spojevi i druga aktivna sredstva za upotrebu u liječenju multiplog mijeloma | |
| JP2022552880A (ja) | 置換４－アミノイソインドリン－１，３－ジオン化合物および組合せ使用のための第２の活性剤 | |
| US20150005262A1 (en) | Hypoxia activated prodrugs and mtor inhibitors for treating cancer | |
| CN107073122A (zh) | 恶性肿瘤的联合治疗 | |
| JPWO2020146440A5 (https=) | ||
| US20200171061A1 (en) | Methods for Cancer Therapy | |
| US20170128389A1 (en) | Paediatric Compositions For Treating Multiple Sclerosis | |
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| KR102904026B1 (ko) | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 | |
| JP2018525411A (ja) | 多発性骨髄腫を治療するためのｂｔｋ阻害剤の組み合わせ | |
| JPWO2021007245A5 (https=) | ||
| BG65472B1 (bg) | Използване на саредутант и неговите фармацевтичноприемливи соли за приготвяне на лекарствено средство за използване за лечение или профилактика на голямо депресивно разтройство | |
| JP6509244B2 (ja) | 水晶体硬化抑制剤 | |
| WO2025078667A1 (en) | Gspt1 molecular glue degrader mrt-2359 for use in the treatment of a myc-driven cancer | |
| CN107708695A (zh) | 用于治疗或预防肺高血压的组合物和方法 | |
| EP2162129B1 (en) | Use of hdac inhibitors for the treatment of bone destruction | |
| CN111989092A (zh) | Bet抑制剂和蛋白酶体抑制剂的联合治疗 | |
| JP2013512195A5 (https=) | ||
| WO2021048412A1 (en) | Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma | |
| WO2021180338A1 (en) | Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant | |
| RU2006126828A (ru) | Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза |